MRNA
NASDAQ · Biotechnology
Moderna Inc
$54.32
-1.94 (-3.44%)
MRNA News26 articles
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
Moderna Plunges 11% as EU Vaccine Deal Lacks Minimum Purchase Guarantee
Moderna stock dropped 11.3% after the EU's RSV vaccine deal lacked a minimum purchase commitment, adding to investor worries about sales and cash burn.
U.S. Futures Dip as June Jobs Data Misses Expectations
U.S. stock futures dipped Friday after ADP reported 98,000 private jobs in June, below forecasts. The 10-year yield neared 4.5%, pressuring banks and real estate. Moderna (MRNA) surged 10%.
Moderna Surges 10% as Flu Vaccine Hopes Add $2.9B to Market Cap
Moderna shares surged over 10% in after-hours trading, adding roughly $2.9 billion in market value as investor enthusiasm for its flu vaccine pipeline continues to build.
Moderna Stock Surges Past Analyst Targets Ahead of FDA Flu Vaccine Decision
Moderna shares surged over 12% Friday to $67.27, now trading above most Wall Street targets ahead of an FDA decision on its mRNA flu vaccine.
US Stock Futures Steady as Focus Shifts to Jobs Report
U.S. stock futures are steady as traders pivot from AI tech to the upcoming June jobs report. The S&P 500 fell 2% last week, led by a 7.9% plunge in semiconductors.
Tech Slide Masks Broader Market Resilience as AI Spending Concerns Mount
U.S. stocks ended mixed as a sharp decline in semiconductor stocks, led by AI-related concerns, triggered nearly $20 billion in tech fund outflows, while the broader market showed resilience.
Moderna Shares Surge on CAR-T Pipeline Plans, Outperform Sector
Moderna shares surged 12.6% after announcing new in vivo CAR-T pipeline plans, closing at $67.27, 52% above the mean analyst target but 14.5% below Piper Sandler's new $77 target.
Tech Selloff Deepens as Chip Index Plunges 5.3%; Jobs Data in Focus
The PHLX chip index fell 5.3% Friday and 7.9% for the week, overshadowing broader market gains. Tech funds lost nearly $20 billion as rising memory costs hit Apple and others. June payrolls data is due Thursday.
Dow Jones Recovers Weekly Gain as Tech Slide Halts Rally Above 52,000
The Dow Jones Industrial Average failed to hold above 52,000 for the third consecutive session, closing at 51,842.08, as a tech slide pressured the broader market.
Tech Sector Sees $20B Outflow as AI Trade Loses Steam
Nearly $20 billion exited tech sector funds last week, wiping out prior record inflows, as AI trade momentum cooled and chip stocks suffered their worst weekly drop since March.
Moderna stock surges $3.3B after unveiling in vivo CAR-T for autoimmune disease
Moderna shares surged 13.9%, adding $3.3 billion in market value after the company unveiled an in vivo CAR-T candidate for autoimmune disease at its Science Day, though near-term sales remain absent.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Moderna Shares Surge on Positive FDA Staff Review for mRNA Flu Vaccine
Moderna shares surged nearly 10% to $57.19 after FDA staff said data on its mRNA flu shot may support effectiveness in adults 65+, lowering regulatory risk ahead of a key advisory panel vote.
Moderna Stock Surges 8% Amid Nasdaq Rally, Cancer Vaccine Progress in Focus
Moderna shares surged nearly 8% to $49.64, tracking a broad Nasdaq rally. Investors are focused on the company's mRNA cancer vaccine pipeline after UK regulators cleared a new trial for Lynch syndrome.
Moderna Shares Surge on Hantavirus Vaccine Interest After Andes Virus Outbreak on Cruise Ship
Moderna shares rose nearly 12% after an Andes virus outbreak on a cruise ship drew attention to its early-stage hantavirus vaccine, though WHO rates public risk low.
Moderna Stock Jumps 12% on Hantavirus Vaccine Deal; Flu and Cancer Pipeline in Focus
Moderna shares rose 11.9% to $54.35 after the company disclosed early-stage hantavirus vaccine research with the U.S. Army and Korea University, following a deadly outbreak on the MV Hondius cruise ship.
Moderna Jumps 10% on Hantavirus Vaccine Push as Cruise Ship Outbreak Revives mRNA Hopes
Moderna shares rose 10% on Friday after the company revealed early-stage work on a hantavirus vaccine, spurred by a deadly Andes virus outbreak on the MV Hondius cruise ship.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Moderna Tops Q1 Revenue Forecast on International Covid Vaccine Sales, Hit by $900M Charge
Moderna's Q1 revenue surged to $389M on international Covid vaccine sales, but a $900M patent charge pushed net loss to $1.34B. Shares fell 2.7%.
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
Moderna Shares Rise on Q4 Beat, Flu Vaccine Faces FDA Hurdle
Moderna shares advanced roughly 5% late Friday after reporting better-than-expected Q4 revenue. The company reaffirmed its 2026 growth targets despite an FDA setback for its seasonal flu vaccine.
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.